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Abstract 
Background and Aims: Nonalcoholic fatty liver disease (NAFLD) has been associated 
with increased cardiovascular risk, including coronary artery disease and cardiac 
dysfunction. In addition, recent evidence highlighted the possible role of epicardial fat as a 
new cardiometabolic risk factor. We tested the correlation between epicardial fat, 
alterations in cardiac geometry and function and the severity of liver damage in patients 
with biopsy-proven NAFLD.  
Methods: The anthropometric, biochemical and metabolic features were recorded in 147 
consecutive biopsy-proven NAFLD cases (Kleiner score). Epicardial fat thickness was 
measured by echocardiography. 
Results: Epicardial fat was higher in patients with severe vs. milder fibrosis (8.5±3.0 vs. 
7.2±2.3 mm; p=0.006); this association was maintained at multivariate logistic regression 
analysis (OR 1.22, 95%C.I. 1.01-1.47; p=0.04) after correction for gender, age>50 years, 
visceral obesity, IFG/diabetes, non-alcoholic steatohepatitis and severe steatosis. Of note 
37.1% of patients with epicardial fat >7mm (median value) had severe liver fibrosis, 
compared to 18.3% of cases with lower epicardial fat (p=0.01). As for echocardiographic 
indices, after adjusting for cardiometabolic confounders, diastolic posterior-wall thickness 
(p=0.01), left ventricular mass (p=0.03), relative wall thickness (p=0.02), and left atrial 
volume (0.04), as well as ejection fraction (p=0.004), lower lateral TDI e’ (p=0.009), E/A 
ratio (0.04) (cardiac geometry alterations and diastolic dysfunction) were linked to severe 
liver fibrosis. 
Conclusions: In patients with NAFLD, a higher epicardial fat thickness is associated with 
the severity of liver fibrosis, in keeping with a possible pathogenic role of ectopic fat depots 
in whole body organ damage. In addition, morphological and functional cardiac alterations 
are more pronounced according to the severity of fibrosis. Further studies are needed to 
validate our results. 
  
INTRODUCTION  
Nonalcoholic fatty liver disease (NAFLD) is increasing worldwide, affecting roughly 20%-
30% of the general population [1]. In addition to an expected risk for disease progression 
from non-alcoholic steatohepatitis (NASH) to bridging fibrosis, cirrhosis and its 
complications [1], NAFLD patients are also at higher risk of early asymptomatic 
cardiovascular alterations and/or frank cardiovascular disease [2]. Specifically, NAFLD, 
diagnosed either by ultrasonography or by liver biopsy, has been associated with a higher 
prevalence of low coronary flow reserve [3], coronary calcification [4], and carotid 
atherosclerosis [5-7] well-before the occurrence of cardiovascular events. These 
alterations have been partly associated with the severity of liver damage, measured by 
both lobular inflammation and fibrosis. Accordingly, cross sectional studies showed an 
association between NAFLD and the presence/extent of coronary, cerebral and peripheral 
cardiovascular involvement [8], whereas longitudinal studies identified NAFLD as a risk 
factor for incident cardiovascular events after adjustment for cardiometabolic confounders 
[9].  
In the last few years a number of studies also assessed the association between 
cardiac morphology or function, and the presence of NAFLD. Specifically, studies in small 
cohorts of subjects at high [10,11] or low [12] cardiometabolic risk highlighted the 
association of an ultrasonographic diagnosis of NAFLD, after adjustment for metabolic 
confounders, with a significant impairment in echocardiographic diastolic function 
compared to non-NAFLD cases. Along this line, a recent study on a small cohort of 
NAFLD patients reported significant changes in cardiac structure and function as assessed 
by MRI, in the absence of metabolic changes or overt cardiac disease [13]. No data were 
however available on the impact of the severity of liver damage on these cardiac 
alterations. The complex interplay between liver fat and heart function has been further 
demonstrated by studies reporting an association between NAFLD and epicardial fat 
  
thickness. Epicardial fat thickness, assessed by either magnetic resonance imaging (MRI) 
[14] or echocardiography [15,16] was higher in NAFLD subjects compared to non-NAFLD, 
and a correlation was reported between epicardial fat thickness and ALT levels [17], the 
severity of ultrasonographic (US) [15] or MR spectroscopy [18] steatosis, and the 
Nonalcoholic Activity Score (NAS) in un-adjusted analyses [16]. 
In a consecutive cohort of patients with biopsy-proven NAFLD, we assessed 
whether epicardial fat is correlated to the severity of liver damage, and whether liver 
damage is linked to cardiac alterations in morphology and function.  
 
Patients and Methods  
Patients 
The study involved 147 consecutive patients with NAFLD, recruited at the Gastrointestinal 
& Liver Unit of Palermo University Hospital, and fulfilling all the inclusion and exclusion 
criteria detailed below. Inclusion criteria were: 1) a histological diagnosis of NAFLD on a 
liver biopsy done less than 6 months before enrollment, showing steatosis (>5% of 
hepatocytes) with or without necroinflammation and/or fibrosis including cirrhosis. The pre-
biopsy assessment of NAFLD was based on chronically elevated ALT for at least 6 months 
and alcohol consumption of <20 g/day in the year before (also confirmed by a 
questionnaire). Exclusion criteria were: (1) decompensated cirrhosis (jaundice, presence 
of ascites or encephalopathy); (2) hepatocellular carcinoma; (3) liver disease of different or 
mixed etiology (excessive alcohol consumption, hepatitis C, hepatitis B, autoimmune liver 
disease, Wilson’s disease, hemochromatosis, α1-antitrypsin deficiency); (4) human 
immunodeficiency virus infection; (5) previous treatment with antiviral therapy, 
immunosuppressive drugs and/or regular use of steatosis-inducing drugs (steroid, 
amiodarone, tamoxifen, etc.), as assessed at interview; (6) history of heart diseases (both 
coronary or cardiac disease); (7) active intravenous drug addiction.  
  
The study was carried out in accordance with the principles of the Helsinki 
Declaration and its appendices, and with local and national laws. Approval was obtained 
from the hospital’s Internal Review Board and its Ethics Committee, and written informed 
consent was obtained from all patients. 
Clinical and Laboratory Assessment 
Clinical and anthropometric data were collected at the time of liver biopsy. Patients 
were classified as normal weight (BMI 18.5-24.9 kg/m2), overweight (BMI 25-29.9), obese 
(BMI ≥30). Waist circumference (WC) was measured at the midpoint between the lower 
border of the rib cage and the iliac crest. Visceral obesity was diagnosed in the presence 
of WC ≥96 cm in males and ≥ 80 cm in females, these thresholds being well applicable to 
Mediterranean/European population [19]. The diagnosis of arterial hypertension was 
based on the following criteria: systolic blood pressure ≥140 mm Hg and/or diastolic blood 
pressure ≥90 mm Hg (measured three times within 30 minutes, in the sitting position and 
using a brachial sphygmomanometer), or use of blood-pressure-lowering agents. The 
diagnosis of impaired fasting glucose (IFG) and of type 2 diabetes was based on the 
revised criteria of the American Diabetes Association, using a value of fasting blood 
glucose ≥100 to <126, and ≥126 mg/dl, respectively [20]. In patients with a previous 
diagnosis of type 2 diabetes, current therapy with insulin or oral hypoglycemic agents was 
documented.  
A 12-hour overnight fasting blood sample was drawn at the time of biopsy to 
determine the serum levels of ALT, total cholesterol, HDL-cholesterol, triglycerides, 
plasma glucose, insulin, and platelet count. Insulin resistance (IR) was determined 
according to the homeostasis model assessment (HOMA) method [21], as: Insulin 
resistance (HOMA-IR)= Fasting insulin (µU/mL) x Fasting glucose (mmol/L)/22.5.  
Assessment of Histology 
  
Slides were coded and read by one pathologist (D.C.), who was unaware of the 
patient’s identity and history. A minimum length of 15 mm of biopsy specimen or the 
presence of at least 10 complete portal tracts was required [22]. Steatosis was assessed 
as the percentage of hepatocytes containing fat droplets (minimum 5%), and evaluated as 
continuous variable. The Kleiner classification [23] was used to grade steatosis, lobular 
inflammation, and hepatocellular ballooning, and to stage fibrosis from 0 to 4.  NASH was 
considered to be present when steatosis, ballooning, and lobular inflammation were all 
present. 
 
Echocardiographic assessment 
Within three months from liver biopsy and before starting educational programs, all 
patients underwent an echocardiography examination by a single experienced observer, 
using a GE VIVID 7 interfaced with a 1.7/2.4 MHz phased-array probe. All recordings were 
digitally stored for off-line analyses by dedicated software, and were later interpreted by 
the same experienced cardiologist who performed the test. 
M-mode echocardiograms of the left ventricle were recorded from the parasternal 
long-axis view guided by two-dimensional image. According to the American Society of 
Echocardiography (ASE) guidelines [24] the following parameters were determined: left 
ventricular telediastolic internal diameter (LVIDd), interventricular septum (IVSTd), and 
posterior wall thickness (PWTd). The relative wall thickness (RWT) was also calculated by 
a formula [(2XPWTd)/LVIDd)], as an index of left ventricular geometry pattern. When 
optimal orientation of LV M-mode ultrasound beam could not be obtained, correctly 
orientated linear dimension measurements were performed using two-dimensional imaging 
[24]. 
The ejection fraction (EF) was calculated at the apical four chamber views. In our 
laboratory the ejection fraction calculated over five consecutive beats shows optimal 
  
reproducibility and accuracy [25]. Left atrial maximal volume was measured at the end of 
left ventricular systole from the apical four chamber views (by the modified Simpson rule) 
[24]. To quantify right ventricle size the basal right ventricle diameter was measured in the 
apical four-chamber view at end-diastole time. 
LV mass was calculated in grams using the following formula: 0.8×(1.04[(LVID + 
IVS + PWT)3 − LVID3]) +0.6. (1) LVM was normalized for height to the 2.7 power 
(LVM/H2.7) [26]. 
The tricuspidal annular plane systolic excursion (TAPSE) was assessed in four-
chamber view, placing the M-mode cursor on the lateral tricuspid annulus. The maximum 
plane systolic excursion of the lateral annulus was measured.  
Pulsed-wave Doppler images at the level of the mitral valve tips from apical four-
chambers two-dimensional views were obtained to measure flow velocities in the peak 
early diastolic (E-wave) and peak late diastolic (A-wave) phase, and to calculate their ratio 
(E/A) and the E-wave deceleration time (DTE), as measurement of diastolic filling. Each 
value was obtained as the average of three measurements.  
Tissue Doppler Imaging (TDI) was used to measure the early peak (e’) of septal and 
lateral mitral annulus velocities. The E/e’ ratio was also calculated using the mean values 
of septal and lateral annulus measurements. 
According to ASE Recommendations for the Evaluation of Left Ventricular Diastolic 
Function [27], the final assessment of diastolic dysfunction considered mitral E, E/A ratio, 
e′ and E/e′ ratio.  
According to the validated Iacobellis’ procedure [28], epicardial fat was measured in 
the parasternal long- and short-axis views that allow the most accurate measurement of 
epicardial adipose tissue of the right ventricle, with optimal cursor beam orientation in each 
view. Because it is compressed during diastole, maximum epicardial fat thickness was 
measured during end systole [28].  
  
 
Statistics 
Continuous variables were summarized as mean ± standard deviation, and categorical 
variables as percentage. The t-test, the chi-square test, and the ANOVA test were used 
when appropriate. Two multiple logistic regression models were used to assess the factors 
independently associated with both NASH (dependent variable, coded as 0=absent or 
1=present) and severe fibrosis (coded as 0= no severe fibrosis (F0-F2) or 1=severe 
fibrosis (F3-F4)). The covariates for the multivariate regression analysis were gender, age 
≥50 years (median value in the population), visceral obesity, impaired fasting 
glucose/diabetes, epicardial fat thickness, NASH (for F3-F4 fibrosis only) and grade 3 
steatosis (for F3-F4 fibrosis only). They were chosen as potential confounders, based on 
their significance in univariate analysis and/or their biological plausibility. 
Multiple linear regression models were used to assess the factors independently 
associated with echocardiographic features among patients stratified by NASH or F3-F4 
fibrosis status. Regression analyses were performed using PROC LOGISTIC, PROC 
REG, and subroutines in SAS [29]. 
 
Patients 
Mean age was 47 years, with a higher prevalence of males (64%). Eighty-five 
percent of patients fitted the criteria for visceral obesity, while IFG/diabetes, diabetes and 
hypertension were observed in 30%, 25% and 35% of subjects. All subjects with diabetes 
or hypertension were drug-treated. Mean values for total, HDL-cholesterol, and 
triglycerides were within the normal range, and 6% of patients were on statins.  
At liver biopsy, two thirds of patients had grade 2-3 steatosis; NASH was diagnosed 
in 76% of cases, and finally one fourth of patients had F3-F4 fibrosis.  
Epicardial fat thickness and severity of liver damage 
  
Mean epicardial fat thickness was 7.5±2.6 mm, and significantly higher in subjects aged 50 
or more  (8.1±2.7 vs. 6.9±2.3 in cases less than 50, p=0.006), viscerally obese (7.8±2.5 vs. 
6.2±2.4, p=0.01), hypertensive (8.2±2.5 vs 7.2±2.6, p=0.03), and statin user (9.2±2.2 vs 
7.4±2.6, p=0.04) patients. 
At multivariate logistic regression analysis, NASH was associated with age >50 
years (OR 3.18, 95%C.I. 1.30-7.74; p=0.01) and visceral obesity (OR 5.27, 95%C.I. 1.76-
15.7; p=0.003). Epicardial fat thickness did not differ according to the presence of NASH 
(7.6±2.5 for NASH vs. 7.4±2.7 for non-NASH, p=0.62), and the severity of steatosis 
(7.5±2.4 for grade 1 vs. 7.2±2.8 for grade 2, 8.0±2.6 for grade 3, p=0.43 by ANOVA).  
Patients with F3-F4 fibrosis had higher epicardial fat thickness compared to their 
counterparts with F0-F2 fibrosis (8.5±3.0 vs. 7.2±2.3, p=0.006) (Figure 1). Of note after 
correction for confounders, including NASH (all patients with F3-F4 fibrosis had NASH) 
and severe steatosis, the association between severe fibrosis and epicardial fat was 
maintained (OR 1.22, 95%C.I. 1.04-1.44; p=0.01) (Table 2). Similar results were obtained 
when HOMA was included in the model instead of IFG/diabetes (data not shown). Of note, 
37.1% of patients with epicardial fat >7 mm had severe liver fibrosis, compared to 18.3% 
of those with epicardial fat ≤7 mm (p=0.01). Along this line, when epicardial fat as 
continuous variable was replaced in the model with epicardial fat as categorical variable 
this last remained significantly associated with F3-F4 fibrosis (OR 2.46, 95%C.I. 1.06-5.71; 
p=0.03) by multivariate logistic regression analysis. 
When considering statin treatment, patients taking statin had no differences in the 
prevalence of NASH or F2-F4 fibrosis (data not shown), but had lower ALT levels (46.6 
±20.1 vs 76.3±46.9, p=0.002) 
Morphological and functional cardiac alterations in NAFLD  
 
Several morphological and functional cardiac alterations were demonstrated in patients 
with NASH, compared with non-NASH. Notably, after adjustment for well-known 
  
cardiometabolic risk factors none of the above quoted associations was maintained (Table 
3). 
Similarly, patients with F3-F4 fibrosis, when compared to F0-F2 fibrosis, presented 
a number of both morphological and functional cardiac alterations (Table 3). After 
correction for cardiometabolic risk factors, F3-F4 fibrosis remained associated not only 
with morphological alterations, like PWTd (p=0.01), LVM/H2.7 (p=0.03), RWT (p=0.02), and 
left atrial volume (p=0.04), but also with functional alterations like EF (p=0.004), lower 
lateral TDI e’ (p=0.009), lower E/A ratio (P=0.04) and marginally with E/e’ (p=0.07) (Table 
3). Similar results were obtained when HOMA was included in the model instead of 
IFG/diabetes (data not shown). 
As for steatosis severity (grade 1 vs. grade 2 vs. grade 3), an association was found 
with LVM (p=0.04) and DTE (p=0.02), but it was not maintained after correction for 
cardiometabolic risk factors (p>0.10 for both). 
 
DISCUSSION 
In a western cohort of biopsy-proven NAFLD patients with a high prevalence of NASH and 
severe liver fibrosis, we observed that epicardial fat thickness is significantly associated 
with the severity of liver fibrosis, and that morphological and functional cardiac alterations 
by echocardiography are inversely related with the severity of liver damage. Of note, these 
associations were maintained after correction for both cardiometabolic and hepatic 
confounders.  
Different lines of clinical studies showed that visceral fat [30], as well as other 
ectopic fat depots like the dorso-cervical fat [31], have a key role in the pathogenesis of 
NAFLD and especially in its histological severity. In the last years growing evidence also 
suggests that the increase in epicardial fat can be considered a cardiometabolic risk factor 
[32], being associated with the metabolic syndrome [33], with a diagnosis of NAFLD both 
  
by US or MR spectroscopy [14-18], with carotid atherosclerosis [34] and coronary artery 
disease [35]. Accordingly, we confirmed the association of epicardial fat thickness with 
older age, visceral obesity, hypertension and statin use, well-known factors associated 
with an increased cardiovascular risk. To the best of our knowledge this is the first study 
showing an independent association between higher epicardial fat thickness and the 
severity of liver fibrosis in NAFLD. Of note this link was maintained after adjustment for 
well-known clinical and metabolic risk factors - including age, blood glucose alterations 
and visceral fat -, as well as histological features, like the presence of NASH and the 
severity of steatosis. Our findings agree with recent data from Iacobellis et al showing a 
direct link between epicardial fat thickness and ALT levels in a cohort of subjects 
with/without HIV infection and with/without metabolic syndrome [36]. However the overlap 
in epicardial fat thickness between our NAFLD patients with high or low hepatic fibrosis 
indicates that this feature is a general risk factor for NAFLD severity more than a measure 
to identify severe fibrosis.  
This study shows that statin users had lower ALT levels compared with their 
counterpart, even if no differences were observed in terms of histological liver damage. 
Our data might suggest a protective effect of statins in NAFLD, as reported in other studies 
on patients taking statins for cardiometabolc disorders [37,38]. 
Another relevant finding of our study is the association of several indices of cardiac 
morphology and function with the severity of liver damage in terms of both NASH and 
severe liver fibrosis. Interestingly, after correction for well-known cardiometabolic risk 
factors (gender, age, visceral obesity, IFG/diabetes and hypertension) severe fibrosis 
maintained its link not only with the parameters of cardiac geometry (left atrial volume, 
LVM/H2.7, PWT and RWT), but also with the indices of diastolic (lateral TDI e’, E/e’, E/A 
ratio) and systolic (EF) function. These results expand previous reports in small cohorts of 
NAFLD patients [10-13], reporting a significant impairment in cardiac structure and 
  
function, as assessed by echocardiography or MRI, in clinically diagnosed NAFLD patients 
compared with subjects without fatty liver. Along this line, our results fit with the evidence 
for an association between liver injury and intima-media thickness [2], another early 
cardiovascular alteration, also present in NAFLD patients. 
 Our study is merely observational and not designed to explore the reasons for the 
association of epicardial fat thickness with liver fibrosis, as well as the link between cardiac 
alterations and the severity of liver damage in NAFLD. However, we may put forward a few 
hypotheses, leaving the demonstration of pathophysiological mechanisms to experimental 
studies. First, increased epicardial fat is able to act as a paracrince/endocrine organ and to 
secrete proatherogenic and proinflammatory adipokines, as tumor necrosis factor alfa, 
interleukin 6, interleukin 1beta and angiotensin [32]. In turn, these chemokines may 
activate stellate cells, leading to liver fibrogenesis.  Second, the independent association 
between liver damage and both morphological and functional cardiac alterations might 
stem from the proinflammatory, proatherogenic and profibrogenic environment 
characterizing patients with NASH and/or advanced fibrosis. This inflammatory state might 
be able to act systemically, affecting the homeostasis of different organs, including the 
heart [2], as already demonstrated for systemic atherosclerosis and kidney damage [6,39]. 
From a clinical point of view and provided our data receive external validation in 
independent NAFLD cohorts, the present results suggest that ecocardiography might be 
useful in patients with steatosis for a global cardiovascular risk assessment and to detect 
cases needing a more intensive diagnostic and therapeutic follow-up. The reported 
functional and morphologic cardiac alterations observed in NAFLD patients with advanced 
fibrosis might have clinical relevance and impact on the future development of heart 
failure, arrhythmias, or other hard cardiovascular outcomes. In turn, the presence of 
increased epicardial fat or other cardiac alterations might identify subgroups of NAFLD 
patients not only at higher cardiovascular risk but also at probably higher risk of severe 
  
liver fibrosis, where a careful assessment of liver disease might be worthy. Finally, the link 
between epicardial fat, cardiometabolic risk factors and severity of liver damage in NAFLD 
further identify in epicardial fat, together with other the well known risk factors another 
potential therapeutic target in NAFLD patients, these data being intriguing due to 
preliminary evidence showing that weight loss is able also to reduce this ectopic fat depot 
[40]. 
The study has both strengths and limits. The strength of our study lies in the 
availability of histological data and their correlation with epicardial fat and cardiac 
alterations. The main limitation is its cross-sectional nature, unable to prove the underlying 
pathogenic mechanisms(s) linking epicardial fat thickness and liver fibrosis, as well as 
cardiac alterations with the severity of liver damage. A further methodological question is 
the potentially limited external validity of the results for different populations and settings. 
Our study included a cohort of Italian NAFLD patients, largely obese, at high prevalence of 
NASH and severe fibrosis, who might be different, in terms of both metabolic features and 
of liver disease severity, from the majority of prevalent NAFLD cases in the general 
population. The lack of data on a control Sicilian population might further limit the strength 
of our results; however literature data already showed a higher epicardial fat thickness and 
a higher prevalence of cardiac alterations in NAFLD compared to subjects without fatty 
liver. The absence of an independent validation cohort further limits the significance of our 
results, which should be replicated in similar cohorts well characterized for both liver and 
cardiac damage. Finally, we also need data on serum levels and on the hepatic expression 
of proinflammatory and profibrogenic cytokines potentially involved in the cardiovascular 
alterations of NAFLD patients.  
In conclusion, in a cohort of Southern-Italy NAFLD patients, we showed that 
epicardial fat thickness is an independent indicator of the severity of liver fibrosis, and that 
the presence of asymptomatic alterations in cardiac geometry and function are inversely 
  
related to the severity of liver damage. The mechanisms underlying these associations 
and their long-term clinical meaning need to be further investigated. 
 
 
 
 
Legend 
Figure 1. Epicardial fat thickness in patients with F3-F4 liver fibrosis compared to patients 
with F0-F2 fibrosis. 
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Table 1. Demographic, Laboratory, Metabolic and Histological Features of 147 Consecutive Patients with Non-
alcoholic Fatty Liver Disease. 
 
 
 
Data are given as mean ± SD or as PERCENTAGE.  
HDL: high-density lipoprotein; HOMA: homeostasis model assessment; IFG: impaired fasting glucose; NASH: 
non-alcoholic steatohepatitis. 
 
 
Variable Non-alcoholic Fatty Liver Disease 
(n=147) 
Mean age – years 48 ± 12  
Male Gender (%) 64 
Mean body mass index – kg/m2 29 ± 4 
Body mass index ≥30– kg/m2 (%) 43 
Visceral Obesity  (%) 85 
Alanine aminotransferase – IU/L 74 ± 46 
Platelet count – 103X mu/L 231 ± 69 
Cholesterol –  mg/dL 202 ± 45 
HDL cholesterol –  mg/dL 52 ± 17 
Triglycerides – mg/dL 136 ± 78 
Blood glucose –  mg/dL 101 ± 33 
Insulin – µU/mL  15 ± 8 
HOMA-score   3.73 ± 2.29 
IFG/Type 2 diabetes (%) 30  
Arterial hypertension (%) 35 
Smoking (%) 24 
Statin use (%) 6 
Histology (%)  
Steatosis grade  
            1 (5%-33%)                                           38 
            2 (>33%-66%) 37 
             3 (>66%) 25 
  
Lobular inflammation  
             0 7 
             1 52 
            2 34 
             3 7 
  
Hepatocellular ballooning  
            0 18 
             1 47 
             2 30 
NASH 76 
  
Stage of Fibrosis  
0 21 
1 31 
2 20 
3 18 
4 10 
  
Table 2. Multivariate Analysis of Risk Factors Associated with Severe Liver Fibrosis (F3-F4)  in 147 
Patients with Non-alcoholic Fatty Liver Disease.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
IFG: impaired fasting glucose. 
 
 
 
 
Variable  
Multivariate Analysis 
OR (95% CI)                           p value 
Female gender 0.59 (0.25 – 1.37)                             0.22 
Age >50 yrs 7.38 (2.51 – 21.6)                           <0.001 
Visceral Obesity 6.77 (0.80 – 57.0)                             0.07 
IFG/Diabetes 2.97 (1.29 – 6.80)                             0.01 
Epicardial fat – mm 1.22 (1.04 – 1.44)                             0.01 
Steatosis grade 3 1.90 (0.80 – 4.49)                             0.14 
  
 
Table 3. Echocardiographic characteristics of NAFLD patients according to NASH and severity of fibrosis in unadjusted and adjusted models.  
 
 
Variable  
 
No NASH 
n=35 
 
 
NASH  
n=112 
 
Univariate 
Analysis 
p value 
p value corrected for 
gender, age>50 yrs, 
visceral obesity, 
hypertension, 
IFG/diabetes, statin use, 
epicardial fat 
  
F0-F2 
Fibrosis 
n=107 
 
 
F3-F4 
Fibrosis 
n=40 
 
Univariate 
Analysis 
p value 
p value corrected for 
gender, age>50 yrs, 
visceral obesity, 
hypertension, 
IFG/diabetes, statin use, 
epicardial fat 
Cardiac Morphology and Systolic Function Parameters (Indexes) 
LVIDd (cm) 4.37 ± 0.34 4.38 ± 0.39  0.84 0.32  4.39 ± 0.39 4.34 ± 0.38  0.44 0.96 
IVSTd (cm) 0.85± 0.10 0.91 ± 0.15  0.02 0.11  0.88 ± 0.12 0.97 ± 0.17  0.001 0.16 
PWTd (cm) 0.84 ± 0.10 0.90 ± 0.12 0.01 0.21  0.86 ± 0.10 0.96 ± 0.14 0.0001 0.01 a 
LVM (g) 118.3 ± 28.8 131.1 ± 33.6 0.04 0.07  123.8 ± 30  139.5 ± 37.8 0.01 0.13 
LVM/h^2.7 (g/m2.7) 29.2 ± 6.9  32.7 ± 7.4   0.01 0.21  30.5 ± 6.2  35.5 ± 9.0  0.0001  0.03b 
RWT  0.38 ± 0.04 0.41 ± 0.06 0.02 0.25  0.39 ± 0.05 0.44 ± 0.08 0.0001 0.02c 
Basal RVd  (cm) 2.93 ± 0.4  3.0 ± 0.3  0.27 0.68  2.96 ± 0.3 3.05 ± 0.3 0.15 0.56 
Left Atrial Volume  (ml) 50.3 ± 12.4 55.0 ± 13.5  0.01 0.66  51.1 ± 11.5 61.2 ± 15.2 <0.001 0.04d 
EF (%) 64.5 ± 3.1 63.5 ± 4.5 0.20 0.06  64.2 ± 3.4 62.4 ± 5.7 0.02 0.004e 
TAPSE (cm) 2.2 ± 0.2 2.2 ± 0.2 0.69 0.55  2.2 ± 0.2 2.1 ± 0.2 0.03 0.28 
Cardiac Diastolic Function Parameters (Indexes) 
E vel (m/sec) 0.71 ± 0.13 0.67 ± 0.14 0.17 0.54  0.69 ± 0.13 0.64 ± 0.13 0.02 0.28 
DTE (ms)   199.8 ± 41.8 220.2 ± 57.2 0.05 0.48  207.8 ± 48.1 235.4 ± 65.4 0.006 0.79 
A vel (m/sec) 0.60 ± 0.15  0.67 ± 0.15 0.03 0.51  0.63 ± 0.15  0.72 ± 0.15 0.001 0.70 
E/A 1.24 ± 0.38 1.06 ± 0.36 0.01 0.34  1.17 ± 0.38 0.91 ± 0.27 0.0001 0.04f 
Septal TDI E’  0.08 ± 0.02 0.07 ± 0.02 0.02 0.63  0.08 ± 0.02 0.06 ± 0.01 0.0001 0.11 
Lateral TDI E’  0.14 ± 0.04 0.12 ± 0.03 0.004 0.13  0.13 ± 0.03 0.10 ± 0.02 0.0001 0.009g 
E/e’ 4.8 ± 1.3 5.2 ± 1.2  0.08 0.78  4.9 ± 1.2 5.8 ± 1.4 0.002 0.07h 
a together with  male gender, hypertension, IGF/diabetes;b together with  hypertension; c together with  hypertension, IGF/diabetes; d together with male gender, obesity, 
hypertension; e together with no statin use; f together with  age>50 yrs, IGF/diabetes; g together with with  age>50 yrs, hypertension, IGF/diabetes; h together with age>50 yrs, 
obesity. 
 
LVIDd: left ventricular  internal diameter diastolic; IVSTd: interventricular septum thickness diastolic; PWTd: posterior wall thickness diastolic; LVM: left ventricular mass; 
LVM/h2.7: left ventricular mass indexed for height to the 2.7 power; RWT: relative wall thickness; Basal RVd: Basal right ventricular diameter; EF: ejection fraction; TAPSE: 
tricuspidal annular plane systolic excursion; E vel: peak early transmitral flow velocity; A vel: peak late transmitral flow velocity; DTE: deceleration time of E velocity; E/A: 
E to A ratio; TDI E’: early annular diastolic tissue velocity by Tissue Doppler Imaging; E/e’: E to e’ ratio . IFG: impaired fasting glucose; NASH: non-alcoholic 
steatohepatitis. 
